Core One Labs’ (COOL.C) wholly-owned subsidiary Akome Biotech announced they are initiating the next step of their clinical development of their patent-pending psychedelic formulations AKO001 and AKO003. The next…
Akome
Core One Labs’ (COOL.C) wholly-owned subsidiary, Akome Biotech, has begun the development of a next-generation psychedelic drug formulation for the purpose of mitigating neurological damage that results from ischemic…
Core One Labs (COOL.C) announced their wholly-owned subsidiary, Akome Biotech, has begun the development of its patent-pending psychedelic drug formulation for the treatment of Alzheimer’s Disease. Akome’s “next-generation” psychedelic…
Core One Labs (COOL.C) announced they have reached a definitive share purchase agreement which will see it acquire all outstanding share capital of Akome Biotech. Akome Biotech’s goal is…